圣湘生物(688289) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 reached ¥1,648.24 million, representing a year-on-year increase of 13.04%[3] - Operating profit decreased to ¥202.43 million, down 27.13% compared to the previous year[3] - Net profit attributable to shareholders was ¥198.15 million, a decline of 28.10% year-on-year[3] - The weighted average return on net assets decreased by 0.96 percentage points to 2.74%[3] Research and Development - R&D investment totaled approximately ¥310 million, accounting for nearly 20% of total revenue[6] - The company launched nearly 20 new Class III medical device products and has over 1,800 cumulative registration certificates[6] - The introduction of the SUREXEVO series, the world's first AI-integrated molecular POCT product, marks a significant technological advancement[6] Strategic Initiatives - Strategic acquisitions included the full acquisition of Zhongshan Haiji and increased investment in AI medical and innovative drug/device sectors[7] - The company established a fund to invest in AI medical and innovative drug/device fields, enhancing its strategic layout[7] Assets - The total assets at the end of the reporting period were ¥9,543.72 million, an increase of 10.92% from the beginning of the period[3]